Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
By W. Harris, E. Mostaghel, P. Nelson, B. Montgomery. Nature Clinical Practice Urology, 2009
835 citations recorded by the source corpus.
Androgen deprivation therapy remains a critical component of treatment for men with advanced prostate cancer, and data support its use in metastatic disease and in conjunction with surgery or radiation in specific settings. Alternatives to standard androgen deprivation therapy, such as intermittent androgen suppression and estrogen therapy, hold the potential to improve toxicity profiles while maintaining clinical benefit. Current androgen deprivation strategies seem to incompletely suppress androgen levels and androgen-receptor-mediated effects at the tissue level. Advances in the understanding of mechanisms that contribute to castration-resistant prostate cancer are leading to rationally designed therapies targeting androgen metabolism and the androgen receptor. The results of large trials investigating the optimization of primary androgen deprivation therapy, including evaluation of intermittent androgen suppression and phase III studies of novel androgen synthesis inhibitors, such as abiraterone acetate, are eagerly awaited.
Subfields: Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/698065c6abc6329b40b4159738672753868e16b6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- C. Crews
- Kanak Raina
- Jing Lu
- Y. Qian
- M. Altieri
- D. Gordon
- AnnMarie K. Rossi
- Kam W. Siu
Citations in the corpus
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer (2016, background): “Until recently, the only treatments approved by the Food and Drug Administration (FDA) for metastatic CRPC were microtubule-disrupting taxanes such as docetaxel and cabazitaxel, which provide only a modest survival benefit (7).”